EAM
MYGN icon

Eagle Asset Management’s Myriad Genetics MYGN Stock Holding History

Eagle Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-351,164
Closed -$6.7M – 554
2022
Q3 		$6.7M Sell
351,164
-9,576
-3% -$220K 0.04% 297
2022
Q2 		$6.55M Sell
360,740
-24,383
-6% -$506K 0.04% 305
2022
Q1 		$9.71M Buy
385,123
+18,874
+5% +$483K 0.05% 276
2021
Q4 		$10.1M Sell
366,249
-14,125
-4% -$409K 0.04% 310
2021
Q3 		$12.3M Buy
380,374
+32,093
+9% +$1.07M 0.06% 275
2021
Q2 		$10.7M Buy
+348,281
New +$10.1M 0.05% 315

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Eagle Asset Management's MYGN Position: Q4 2022 in Review

Eagle Asset Management sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 351,164 shares — an estimated $6.7M sold.

Eagle Asset Management first reported a position in MYGN in Q2 2021 and held it in 6 quarters. The position peaked at $12.3M in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

  • Eagle Asset Management reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
  • Eagle Asset Management sold 351,164 Myriad Genetics shares in Q4 2022, an estimated $6.7M.
  • Eagle Asset Management first reported a position in Myriad Genetics in Q2 2021 and held it in 6 quarters.
  • Eagle Asset Management's Myriad Genetics position peaked at $12.3M in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Eagle Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.